Article Information
History
- January 20, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Naveenchandra Suryadevara1,#,
- Swathi Shrihari4,#,
- Pavlo Gilchuk1,
- Laura A. VanBlargan4,
- Elad Binshtein1,
- Seth J. Zost1,
- Rachel S. Nargi1,
- Rachel E. Sutton1,
- Emma S. Winkler3,4,
- Elaine C. Chen5,
- Mallorie E. Fouch6,
- Edgar Davidson6,
- Benjamin J. Doranz6,
- Robert H. Carnahan1,7,
- Larissa B. Thackray4,*,
- Michael S. Diamond2,3,4,8,* and
- James E. Crowe Jr.1,5,7,*
- 1Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
- 2Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO, 63110, USA
- 3Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, 63110, USA
- 4Department of Medicine, Washington University School of Medicine, Saint Louis, MO, 63110 USA
- 5Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
- 6Integral Molecular, Philadelphia, PA, 19104, USA
- 7Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
- 8Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, 63110, USA
- ↵*Corresponding authors. Lead Contact: james.crowe{at}vumc.org
↵# These authors contributed equally.
Posted January 20, 2021.
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
